Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Allogene Therapeutics, Inc.
  6. Summary
    ALLO   US0197701065

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
Delayed Nasdaq  -  04:00:00 2023-06-02 pm EDT
5.610 USD   +5.45%
06/03Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
06/03Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
GL
06/03Allogene Therapeutics, Inc. Presents Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials of ALLO-501/501A in Patients with Relapsed/Refractory Large B-Cell Lymphoma at American Society of Clinical Oncology Annual Meeting in Chicago, Illinois
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/26/2023 05/30/2023 05/31/2023 06/01/2023 06/02/2023 Date
5.53(c) 5.19(c) 5.25(c) 5.32(c) 5.61(c) Last
1 258 574 2 372 117 1 721 812 1 336 965 1 545 141 Volume
+1.10% -6.15% +1.16% +1.33% +5.45% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 0,08 M - -
Net income 2023 -346 M - -
Net cash position 2023 158 M - -
P/E ratio 2023 -2,38x
Yield 2023 -
Sales 2024 0,03 M - -
Net income 2024 -364 M - -
Net cash position 2024 116 M - -
P/E ratio 2024 -2,45x
Yield 2024 -
Capitalization 818 M 818 M -
EV / Sales 2023 8 777x
EV / Sales 2024 25 815x
Nbr of Employees 360
Free-Float 58,0%
More Financials
Company
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer. It is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced T cell... 
Read more
Sector
Biotechnology & Medical Research
Calendar
06/03 | 04:00pmPresentation
More about the company
Ratings of Allogene Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ALLOGENE THERAPEUTICS, INC.
06/03Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymph..
AQ
06/03Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymph..
GL
06/03Allogene Therapeutics, Inc. Presents Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2..
CI
05/24Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
GL
05/12Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/5..
AQ
05/11Allogene Therapeutics, Inc. Announces Encore Presentation of Phase 1 Data from the Allo..
CI
05/11Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/5..
GL
05/10Transcript : Allogene Therapeutics, Inc. Presents at Bank of America Securiti..
CI
05/05JMP Securities Adjusts Allogene Therapeutics' Price Target to $15 From $19, Keeps Outpe..
MT
05/04Stifel Nicolaus Adjusts Allogene Therapeutics Price Target to $7.50 From $8, Maintains ..
MT
05/03Transcript : Allogene Therapeutics, Inc., Q1 2023 Earnings Call, May 03, 2023
CI
05/03Allogene Therapeutics : Q1 Earnings Snapshot
AQ
05/03ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/03Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/03Allogene Therapeutics, Inc. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
News in other languages on ALLOGENE THERAPEUTICS, INC.
06/03Allogene Therapeutics, Inc. Allogene Therapeutics Inc. présente les résultats du suivi ..
05/11Allogene Therapeutics, Inc. Allogene Therapeutics Inc. annonce une nouvelle présentatio..
05/03Allogene Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 ..
04/21Allogene Therapeutics, Inc. nomme Timothy Moore vice-président exécutif et directeur te..
04/20Alison Moore, directrice technique d'Allogene Therapeutics, Inc. démissionne le 28 avri..
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
ETFs positioned on ALLOGENE THERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Loncar Cancer Immunotherapy ETF - USD3.25%2.95%-World
CI Bio-Revolution ETF - CAD1.58%0.22%-NC
Direxion Fallen Knives ETF - USD1.38%-9.78%-NC
IShares Genomics Immunology and Healthcare ...1.15%2.16%World
Global X Genomics & Biotechnology ETF - USD0.99%3.23%NC
More ETFs positioned on ALLOGENE THERAPEUTICS, INC.
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 5,61 $
Average target price 16,91 $
Spread / Average Target 201%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Barbra Sasu Chief Scientific Officer
Zachary Roberts Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-10.81%818
VERTEX PHARMACEUTICALS INCORPORATED15.58%85 966
REGENERON PHARMACEUTICALS, INC.1.34%79 256
WUXI APPTEC CO., LTD.-16.25%28 067
BIONTECH SE-28.02%26 058
GENMAB A/S-7.45%25 588
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer